Evidence map›Paper›PMID 38483868›Full record

ArticlePloS one2024

A measles IgM rapid diagnostic test to address challenges with national measles surveillance and response in Malaysia.

A'aisah Senin, Noorliza M Noordin, Jamiatul A M Sani, Diana Mahat, Morgane Donadel, Heather M Scobie, Aziyati Omar, Yu K Chem, Mohamad I Zahari, Fatanah Ismail and 16 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 5 countries.

A'aisah SeninDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Noorliza M NoordinDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Jamiatul A M SaniDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Diana MahatDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Morgane DonadelGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0001-6448-9587
Heather M ScobieGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Aziyati OmarNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Yu K ChemNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Mohamad I ZahariDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Fatanah IsmailFamily Health Development Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Rozita A RahmanFamily Health Development Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Hani M HussinDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Sengol SelvanesanNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Zirwatul A AzizNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
W N Afiza W M ArifinNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Rehan S A BakarNational Public Health Laboratory, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
Norhayati RusliDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
M Hanif ZailaniDisease Control Division, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.ORCID 0000-0002-9466-2798
Paul SooOffice of the World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, Cyberjaya, Malaysia.
Ying-Ru LoOffice of the World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, Cyberjaya, Malaysia.ORCID 0000-0002-7527-7819
Varja GrabovacWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Paul A RotaDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Mick N MuldersDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
David FeatherstoneConsultant Scientists Ltd, Auckland, NewZealand.
Lenesha WarrenerPublic Health Microbiology Division, United Kingdom Health Security Agency (UKHSA), London, United Kingdom.
David W BrownPublic Health Microbiology Division, United Kingdom Health Security Agency (UKHSA), London, United Kingdom.
Ministry of Health · MYCenters for Disease Control and Prevention · USWorldFish · MYFundação Oswaldo Cruz · BRWorld Health Organization · CHWorld Health Organization Regional Office for the Western Pacific · PH

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionA lateral flow rapid diagnostic test (RDT) enables detection of measles specific immunoglobulin M (IgM) antibody in serum, capillary blood, and oral fluid with accuracy consistent with enzyme immunoassay (EIA). The objectives of the study were: 1) to assess measles RDT inter-reader agreement between two clinic staff; 2) to assess the sensitivity and specificity of the measles RDT relative to standard surveillance testing in a low transmission setting; 3) to evaluate the knowledge, attitudes, and practices of staff in clinics using the RDT; and 4) to assess the impact of RDT testing on the measles public health response in Malaysia. MATERIALS AND

methodsThe clinic-based prospective evaluation included all suspected measles cases captured by routine measles surveillance at 34 purposely selected clinics in 15 health districts in Malaysia between September 2019 and June 2020, following day-long regional trainings on RDT use. Following informed consent, four specimens were collected from each suspected case, including those routinely collected for standard surveillance [serum for EIA and throat swabs for quantitative reverse transcriptase polymerase chain reaction (RT-qPCR)] together with capillary blood and oral fluid tested with RDTs during the study. RDT impact was evaluated by comparing the rapidity of measles public health response between the pre-RDT implementation (December 2018 to August 2019) and RDT implementation periods (September 2019 to June 2020). To assess knowledge, attitudes, and practices of RDT use, staff involved in the public health management of measles at the selected sites were surveyed.

resultsAmong the 436 suspect cases, agreement of direct visual readings of measles RDT devices between two health clinic staff was 99% for capillary blood (k = 0.94) and 97% for oral fluid (k = 0.90) specimens. Of the total, 45 (10%) were positive by measles IgM EIA (n = 44, including five also positive by RT-qPCR) or RT-qPCR only (n = 1), and 38 were positive by RDT (using either capillary blood or oral fluid). Using measles IgM EIA or RT-qPCR as reference, RDT sensitivity using capillary blood was 43% (95% CI: 30%-58%) and specificity was 98% (95% CI: 96%-99%); using oral fluid, sensitivity (26%, 95% CI: 15%-40%) and specificity (97%, 95% CI: 94%-98%) were lower. Nine months after training, RDT knowledge was high among staff involved with the public health management of measles (average quiz score of 80%) and was highest among those who received formal training (88%), followed by those trained during supervisory visits (83%). During the RDT implementation period, the number of days from case confirmation until initiation of public response decreased by about 5 days.

conclusionThe measles IgM RDT shows >95% inter-reader agreement, high retention of RDT knowledge, and a more rapid public health response. However, despite ≥95% RDT specificity using capillary blood or oral fluid, RDT sensitivity was <45%. Higher-powered studies using highly specific IgM assays and systematic RT-qPCR for case confirmation are needed to establish the role of RDT in measles elimination settings.

Indexed as

MeaslesRapid Diagnostic TestsHumansImmunoenzyme TechniquesImmunoglobulin MMalaysiaSensitivity and SpecificityImmunoglobulin M

Identifiers

PMID38483868
PMCPMC10939268
OpenAlexW4392818640

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.